FDA Approves Lirafugratinib for Advanced FGFR2+ Cholangiocarcinoma

The U.S. Food and Drug Administration (FDA) approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.) on September 23, 2026, for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement. Lirafugratinib is an oral kinase inhibitor that targets altered FGFR2 signaling pathways involved in biliary tract oncogenesis and cellular proliferation.

Cholangiocarcinoma is a rare, aggressive malignancy originating in the bile ducts, with FGFR2 fusions or rearrangements present in approximately 10% to 15% of intrahepatic cases.

Clinical Efficacy Data From the REFOCUS Trial

Regulatory approval was supported by clinical safety and efficacy outcomes from REFOCUS (NCT04526106), a multicenter, open-label, single-arm phase 2 trial. The trial evaluated 116 adult patients with unresectable or metastatic cholangiocarcinoma harboring confirmed FGFR2 gene fusions or rearrangements. All enrolled participants were naïve to prior FGFR inhibitor therapy and had experienced disease progression following at least one prior systemic regimen containing chemotherapy or chemoimmunotherapy. Trial participants received oral lirafugratinib at a recommended dose of 70 mg once daily until disease progression or unacceptable toxicity.

Major efficacy outcome measures evaluated in the trial were objective response rate (ORR) and duration of response (DOR), assessed by an independent review committee using Response Evaluation Criteria in Solid Tumors (RECIST v1.1). Treatment with lirafugratinib yielded an ORR of 46% (95% CI: 36, 55). The median DOR was 11.8 months (95% CI: 7.5, 13.0).

Key Clinical Takeaways for Oncology Nurses: Efficacy and Trial Parameters

• Target Population Verification: Confirm that patients have confirmed FGFR2 gene fusions or rearrangements and previously treated, unresectable, locally advanced, or metastatic disease prior to therapy initiation.
• Prior Treatment History: Ensure patients are naïve to prior FGFR inhibitor therapy and have progressed following systemic chemotherapy or chemoimmunotherapy regimens.
• Efficacy Metrics: Clinical trial results from the REFOCUS study (NCT04526106) demonstrate an ORR of 46% and a median DOR of 11.8 months in 116 evaluable patients.
• Standard Dosing Schedule: Administer lirafugratinib at a dose of 70 mg orally once daily continuously until disease progression or unmanageable toxicity.

Regulatory Pathways and Dosing Guidelines

The FDA review utilized the Real-Time Oncology Review (RTOR) pilot program, which enabled regulatory teams to evaluate clinical data components prior to full application submission. Evaluation was further facilitated by the Assessment Aid, a voluntary applicant submission designed to streamline agency assessment. The FDA granted priority review, breakthrough therapy designation, and orphan drug designation to lirafugratinib.

The recommended dosage of lirafugratinib is 70 mg taken orally once daily. Patients should be instructed to take their medication at approximately the same time each day to maintain stable plasma concentrations.

Safety Profile, Warnings, and Adverse Event Management

The prescribing information for lirafugratinib includes warnings and precautions regarding ocular toxicity, hyperphosphatemia and soft tissue mineralization, and embryo-fetal toxicity.

Class-specific toxicities associated with FGFR inhibitors require systematic clinical monitoring. Ocular toxicities, including retinal pigment epithelial detachment (RPED), ocular surface dryness, and visual disturbances, necessitate baseline and routine ophthalmologic assessments.

Hyperphosphatemia is a expected pharmacodynamic outcome of FGFR inhibition on renal phosphate handling. Nursing management requires monitoring serum phosphate levels, guiding dietary phosphate restriction, and initiating phosphate-binder therapy or dose holds when serum levels exceed defined thresholds. Soft tissue mineralization may develop secondary to prolonged hyperphosphatemia. Due to potential embryo-fetal toxicity, verified pregnancy status and effective contraception are required during treatment.

Key Clinical Takeaways for Oncology Nurses: Safety and Patient Care

• Baseline Eye Examinations: Coordinate baseline ophthalmologic evaluations, including optical coherence tomography, and monitor for changes in visual acuity or dry eye symptoms throughout treatment.
• Serum Phosphate Surveillance: Obtain baseline serum phosphate levels and conduct regular lab monitoring to manage hyperphosphatemia through dietary adjustments and phosphate binders.
• Toxicity Intervention Protocols: Apply institutional protocols for temporary treatment holds, dose reductions, or discontinuation when patients experience severe hyperphosphatemia or ocular adverse events.
• Reproductive Safety Counseling: Verify pregnancy status in females of reproductive potential before starting treatment and reinforce the necessity of effective contraception during therapy.
• Adverse Event Reporting: Report suspected serious adverse reactions to the FDA MedWatch Reporting System or Ocean Center of Excellence's Project Facilitate.

Reference

• U.S. Food and Drug Administration. FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma. Published September 23, 2026. Accessed September 23, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic